EP2347009A4 - Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signaturensets nach tumortyp - Google Patents

Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signaturensets nach tumortyp

Info

Publication number
EP2347009A4
EP2347009A4 EP09821173A EP09821173A EP2347009A4 EP 2347009 A4 EP2347009 A4 EP 2347009A4 EP 09821173 A EP09821173 A EP 09821173A EP 09821173 A EP09821173 A EP 09821173A EP 2347009 A4 EP2347009 A4 EP 2347009A4
Authority
EP
European Patent Office
Prior art keywords
tumors
genetic
type
protein targets
biomarker profiles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09821173A
Other languages
English (en)
French (fr)
Other versions
EP2347009A2 (de
Inventor
Hoff Daniel D Von
Robert J Penny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caris Life Sciences Inc
Original Assignee
Caris MPI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris MPI Inc filed Critical Caris MPI Inc
Priority to EP16158951.0A priority Critical patent/EP3075864A1/de
Publication of EP2347009A2 publication Critical patent/EP2347009A2/de
Publication of EP2347009A4 publication Critical patent/EP2347009A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Databases & Information Systems (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Primary Health Care (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioethics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
EP09821173A 2008-10-14 2009-10-14 Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signaturensets nach tumortyp Withdrawn EP2347009A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16158951.0A EP3075864A1 (de) 2008-10-14 2009-10-14 Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signatursets nach tumortyp

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10533508P 2008-10-14 2008-10-14
US10692108P 2008-10-20 2008-10-20
PCT/US2009/060630 WO2010045318A2 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP16158951.0A Division EP3075864A1 (de) 2008-10-14 2009-10-14 Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signatursets nach tumortyp

Publications (2)

Publication Number Publication Date
EP2347009A2 EP2347009A2 (de) 2011-07-27
EP2347009A4 true EP2347009A4 (de) 2012-05-30

Family

ID=42107198

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09821173A Withdrawn EP2347009A4 (de) 2008-10-14 2009-10-14 Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signaturensets nach tumortyp
EP16158951.0A Withdrawn EP3075864A1 (de) 2008-10-14 2009-10-14 Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signatursets nach tumortyp

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16158951.0A Withdrawn EP3075864A1 (de) 2008-10-14 2009-10-14 Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signatursets nach tumortyp

Country Status (6)

Country Link
US (5) US20100113299A1 (de)
EP (2) EP2347009A4 (de)
CN (2) CN106153918A (de)
CA (1) CA2739675C (de)
IL (1) IL212349A0 (de)
WO (1) WO2010045318A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1942937A1 (de) 2005-11-04 2008-07-16 Wyeth Antitumor-kombinationen mit mtor-hemmer, herceptin und/oder hki-272
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) * 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
EP3360978A3 (de) 2009-05-07 2018-09-26 Veracyte, Inc. Verfahren zur diagnose von schilddrüsenerkrankungen
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US8338456B2 (en) 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
EP2619329B1 (de) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direkte erfassung, amplifikation und sequenzierung einer ziel-dna unter verwendung immobilisierter primer
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
CN102094084B (zh) * 2010-11-24 2012-09-19 中山大学附属第三医院 检测EphA2基因表达量的荧光定量PCR方法及试剂盒与应用
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US20130254547A1 (en) * 2012-03-23 2013-09-26 International Business Machines Corporation Encrypted transmission to and storage of surprisal data
US10353869B2 (en) 2012-05-18 2019-07-16 International Business Machines Corporation Minimization of surprisal data through application of hierarchy filter pattern
EP2885640B1 (de) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostatakrebsprognostik mittels biomarkern
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3314027A4 (de) 2015-06-29 2019-07-03 Caris Science, Inc. Therapeutische oligonukleotide
US10941176B2 (en) 2015-07-28 2021-03-09 Caris Science, Inc. Therapeutic oligonucleotides
US10731166B2 (en) 2016-03-18 2020-08-04 Caris Science, Inc. Oligonucleotide probes and uses thereof
WO2017205686A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3504348B1 (de) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Verwendung von genomischen signaturen zur vorhersage des ansprechens von patienten mit prostatakrebs auf postoperative strahlentherapie
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
EP3888021B1 (de) 2018-11-30 2024-02-21 Caris MPI, Inc. Molekulare profilierung der nächsten generation
CA3163319A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
WO2025255578A1 (en) 2024-06-07 2025-12-11 Caris Mpi, Inc. Dual-modality models for digital pathology

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013431A (en) * 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US5610281A (en) * 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5710001A (en) * 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5837492A (en) * 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
DE69625678T3 (de) * 1995-12-18 2006-11-09 The University Of Utah Research Foundation, Salt Lake City Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
US6150514A (en) * 1997-04-09 2000-11-21 University Of Utah Research Foundation 14 Kilobase deletion in the promoter region of BRCA1 in a breast cancer family
WO2000024940A1 (en) * 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
CN1231761C (zh) * 1998-12-23 2005-12-14 梅德塞克股份有限公司 一种检测装置及鉴定分子的方法
US6613510B2 (en) * 1999-04-28 2003-09-02 Mayo Foundation For Medical Education And Research Methods and probe sets for determining prostate cancer prognosis
US20040033490A1 (en) * 2000-03-31 2004-02-19 Laird Peter W. Epigenetic sequences for esophageal adenocarcinoma
US6812023B1 (en) * 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
DE10043591A1 (de) * 2000-09-01 2002-03-14 Max Delbrueck Centrum Verfahren zur Erfassung von Resistenz-Profilen von Geweben und Zellinien
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
AU2002217904A1 (en) * 2000-11-28 2002-06-11 Surromed, Inc. Methods for efficiently minig broad data sets for biological markers
DE60235088D1 (de) * 2001-07-05 2010-03-04 Taiho Pharmaceutical Co Ltd Dna-arrays zur messung der empfindlichkeit gegenüber einem antikrebsmittel
US7529685B2 (en) * 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
EP1456364B1 (de) * 2001-12-21 2011-03-23 The Wellcome Trust Mutationen im b-raf-gen
JP3481231B2 (ja) * 2002-03-05 2003-12-22 三洋電機株式会社 有機エレクトロルミネッセンス表示装置およびその製造方法
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
AU2003253629A1 (en) * 2002-06-07 2003-12-22 Myriad Genetics, Inc Large deletions in human brca1 gene and use thereof
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
CA2504605C (en) * 2002-11-13 2016-01-19 Thomas Jefferson University Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15
WO2004074518A1 (en) * 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
WO2004089073A2 (en) * 2003-04-03 2004-10-21 Genpath Pharmaceuticals, Incorporated Inducible breast cancer model
EP1613350B1 (de) * 2003-04-09 2009-03-18 Genentech, Inc. Behandlung von autoimmunkrankheit bei einem patienten mit unzureichendem ansprechen auf einen tnf-alpha-hemmer
US7361460B2 (en) * 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
US20050084913A1 (en) * 2003-04-22 2005-04-21 Maxygen, Inc. Novel tumor-associated antigens
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7319007B2 (en) * 2003-06-12 2008-01-15 Pomeranian Academy Of Medicine Determining a predisposition to cancer
AU2004249193A1 (en) * 2003-06-20 2004-12-29 Amgen Inc. Gene amplification and overexpression in cancer
AU2004258085B2 (en) * 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
ATE403755T1 (de) * 2003-08-28 2008-08-15 Ipsogen Identifizierung einer erbb2- genexpressionssignatur bei brustkrebs
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
ES2636470T3 (es) * 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
JP5697297B2 (ja) * 2004-05-14 2015-04-08 ロゼッタ ジノミクス リミテッド マイクロｎａｓおよびその使用
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
ES2537631T3 (es) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
ES2787454T3 (es) * 2004-09-30 2020-10-16 Epigenomics Ag Método para proveer fragmentos de ADN derivados de una muestra archivada
US7595159B2 (en) * 2004-11-03 2009-09-29 The Brigham And Women's Hospital, Inc. Prediction of Parkinson's disease using gene expression levels of peripheral blood samples
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
AU2006234897A1 (en) * 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
US20090061422A1 (en) * 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1872124A4 (de) * 2005-04-19 2008-06-11 Prediction Sciences Llc Diagnosemarker für brustkrebsbehandlung und -progression sowie verfahren zur verwendung davon
EP1722230A3 (de) * 2005-04-27 2009-05-27 MPB MelTec Patent- und Beteiligungsgesellschaft mbH Verfahren für den Nachweis eines krankheitsspezifischen kombinatorischen Molekularstrukturmotivs in einer Hautgewebeprobe eines Patienten
US20090118175A1 (en) * 2005-05-06 2009-05-07 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
US20070020657A1 (en) * 2005-05-20 2007-01-25 Grebe Stefan K Methods for detecting circulating tumor cells
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070134687A1 (en) * 2005-09-12 2007-06-14 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
CA2624086A1 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
EP1945802A1 (de) * 2005-10-12 2008-07-23 Erasmus University Medical Center Rotterdam Verfahren zur diagnose oder zum screening entzündlicher krankheiten
CA2628255C (en) * 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20090215642A1 (en) * 2005-12-09 2009-08-27 Knudson Alfred G Methods and Compositions for Assessing Alterations in Gene Expression Patterns in Clinically Normal Tissues Obtained from Heterozygous Carriers of Mutant Genes Associated with Cancer and Methods of Use Thereof
JP2007175021A (ja) * 2005-12-28 2007-07-12 Sysmex Corp 大腸がんのリンパ節転移マーカー
US7593913B2 (en) * 2006-01-11 2009-09-22 Siemens Medical Solutions Usa, Inc. Systems and method for integrative medical decision support
WO2007103541A2 (en) * 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
CA2648021A1 (en) * 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
US20090098538A1 (en) * 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
WO2007145862A2 (en) * 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
CN103424541B (zh) * 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8288369B2 (en) * 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
US20080014598A1 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Phospho-specific antibodies to pi3k regulatory subunit and uses thereof
WO2008009002A2 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2008017992A2 (en) * 2006-08-11 2008-02-14 Koninklijke Philips Electronics, N.V. Systems and methods for associating nucleic acid profiles and proteomic profiles with healthcare protocols and guidelines in a decision support system
EP1892303A1 (de) * 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Identifizierung von therapeutischen Zielen in Tumoren und zum Nachweis und Therapie von Lungenadenokarzinom-assoziierten Angiogenese und Hämostase
US20090280493A1 (en) * 2006-09-08 2009-11-12 Siemens Healthcare Diagnostics Inc. Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia
CA2667737A1 (en) * 2006-10-27 2008-05-02 Julius Gudmundsson Cancer susceptibility variants on chr8q24.21
EP2120909A2 (de) * 2006-12-15 2009-11-25 Ordway Research Institute Behandlung von therapierefraktären erkrankungen, umfassend arzneimittelkombinationen
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
US20080226645A1 (en) * 2007-01-10 2008-09-18 Wyeth Methods and compositions for assessment and treatment of asthma
ATE535805T1 (de) * 2007-01-26 2011-12-15 Univ Louisville Res Found Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
CN101641010A (zh) * 2007-01-26 2010-02-03 路易斯维尔大学研究基金会公司 用作疫苗的外来体组分的修饰
EP2129791A4 (de) * 2007-02-26 2010-07-28 Wayne John Cancer Inst Nutzen der b-raf-dna-mutation für die diagnose und behandlung von krebs
CA2706881A1 (en) * 2007-11-30 2009-06-11 Brian Z. Ring Tle3 as a marker for chemotherapy
EP2294215B1 (de) * 2008-05-12 2013-01-16 Genomic Health, Inc. Tests zur vorhersage der ansprechrate von krebspatienten auf chemotherapeutische behandlungsoptionen
US20100069298A1 (en) * 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GYURKOCZA BOGLARKA ET AL: "Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors", JOURNAL OF THE NATIONAL CANCER INSTITUTE (CARY), vol. 98, no. 15, August 2006 (2006-08-01), pages 1068 - 1077, XP002672777, ISSN: 0027-8874 *
PADUANO FRANCESCO ET AL: "Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 1, January 2006 (2006-01-01), pages 179 - 186, XP002672776, ISSN: 1535-7163 *

Also Published As

Publication number Publication date
US20140149137A1 (en) 2014-05-29
EP2347009A2 (de) 2011-07-27
CN102232117A (zh) 2011-11-02
CN106153918A (zh) 2016-11-23
CA2739675A1 (en) 2010-04-22
US20140057986A1 (en) 2014-02-27
CA2739675C (en) 2020-12-01
IL212349A0 (en) 2011-06-30
EP3075864A1 (de) 2016-10-05
US20140149136A1 (en) 2014-05-29
US20120015843A1 (en) 2012-01-19
US20100113299A1 (en) 2010-05-06
WO2010045318A3 (en) 2010-08-19
WO2010045318A2 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
EP2347009A4 (de) Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signaturensets nach tumortyp
BRPI0916229A2 (pt) assinaturas e determinantes pcs associados com câncer de próstata e métodos de utilização dos mesmos
WO2012030840A9 (en) Gene signatures for cancer diagnosis and prognosis
EP2198021A4 (de) Ebi3, dlx5, nptx1 und cdkn3 für zielgene der lungenkrebstherapie und -diagnose
PL2800811T3 (pl) Sposoby i kompozycje do kierowanej RNA modyfikacji docelowego DNA i do modulacji transkrypcji kierowanej RNA
ZA201305024B (en) Colon cancer gene expression signatures and methods of use
IL250931A0 (en) Detection of genetic or molecular aberrations associated with cancer
EP2361988A4 (de) Molekularer marker für krebsstammzelle
MX390699B (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
BR112013002299A2 (pt) método de captura e sequenciamento de uma molécula alvo de ácido nucleíco e método de determinação do estado de metilação de um fragmento de dna genônimo
BRPI0811755A2 (pt) Amplificação específica de senquência de dna específicas de tumor.
PL2188379T3 (pl) Kompleksy RNA i peptydów kationowych do transfekcji i do immunostymulacji
BRPI0921096A2 (pt) Composições e métodos para inibir a expressão dos genes de fator vii
EP2294200A4 (de) Neue biosynthese-gene
DK3597761T3 (da) Prostatacancercellelinjer, gensignaturer og anvendelser deraf
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
GB0811413D0 (en) Gene expression signatures for lung cancers
EP2382330A4 (de) Kreuzpräsentierte verstärkung von target-nukleinsäuren
EP2744919A4 (de) Gensignaturen für lungenkrebsprognose und therapieauswahl
ATE534738T1 (de) Mir-126-regulierte gene und pfade als ziele für therapeutische interventionen
EP2285983A4 (de) Verwendung von runx3 und mir-532-5p als krebsmarker und -therapieziele
BRPI0909063A2 (pt) Amplificação de alvo e sequenciamento com iniciadores compreendendo unidades monoméricas de formação de tripla.
WO2008137089A3 (en) Gene signature of early hypoxia to predict patient survival
BRPI0910448A2 (pt) síntese dos aglutinantes melhorados e taticidade modificada
EP2627787A4 (de) Multiplexierte quantitative erkennung von nukleinsäuretargets

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110516

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G06F 19/00 20110101ALI20120412BHEP

Ipc: C12N 15/12 20060101ALI20120412BHEP

Ipc: C12Q 1/68 20060101AFI20120412BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120426

17Q First examination report despatched

Effective date: 20130919

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160308